ICON
Groningen, 9728 NZ, Netherlands
NCT Number: NCT06166992
The main objective of this trial is to investigate the absolute bioavailability of BI 1291583 (test treatment T, not radio-labelled) compared with BI 1291583 (C-14) (reference treatment R).
Looking for future studies?
Notify Me18 year–55 year
Male
Interventional
Phase 1
Groningen, 9728 NZ, Netherlands
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
BI 1291583
Other names: Verducatib
[14C]-BI 1291583
Other names: Verducatib
Time frame: Up to 10 days
Time frame: Up to 10 days
Time frame: Up to 10 days
Boehringer Ingelheim
Industry
Investigation of Pharmacokinetics and Absolute Oral Bioavailability of BI 1291583 Administered as an Oral Dose With an Intravenous Microtracer Dose of [14C]-BI 1291583 in Healthy Male Volunteers
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06068257
Breast Cancer, Breast Diseases
Orlando, Florida, United States
View Trial DetailsNCT06702423
Healthy
London, United Kingdom
View Trial DetailsNCT07223164
Healthy
Irvine, California, United States
View Trial DetailsNCT05595902
Healthy
Kadıköy, Istanbul, Turkey (Türkiye)
View Trial Details